Value proposition

Developing selective inhibitors of CTPS1 for patients with cancer and auto-immune diseases

Step Pharma is the world leader in the discovery and development of inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases.
Step Pharma’s lead program dencatistat (STP938) is a first in class, potent, selective, oral inhibitor of CTPS1 with demonstrated anti-tumor activity. Dencatistat entered clinical development in 2022 in a PhI/II study for the treatment of relapsed and refractory T-cell and B-cell lymphoma. More recently a solid tumour study was started focused on ovarian cancer using the concept of synthetic lethality and biomarker selection of patients. This can ultimately be viewed as a tumour agnostic approach with ovarian cancer being the PoC indication and future plans to expand into other tumour types such as NSCLC with high prevalence of the biomarker.